The present invention relates to substituted 5-membered nitrogen containing heteroaryl compounds, such as sulfonyl triazoles, where the heteroaryl ring is further substituted, optionally via a linking group such as -NH-, with a cyclic group which in turn is substituted at the α-position. The present invention further relates to associated salts, solvates, prodrugs and pharmaceutical compositions, and to the use of such compounds in the treatment and prevention of medical disorders and diseases, most especially by NLRP3 inhibition.
Thieno[2,3-d]pyrimidinediones and their use as pharmaceuticals
申请人:——
公开号:US20040014634A1
公开(公告)日:2004-01-22
The invention provides thieno[2,3-d]pyrimidinediones of general formula (I), wherein R, R
1
, R
2
and R
3
are as defined in the specification, processes for their production, pharmaceutical compositions containing them and their use in therapy.
1
[EN] TRIAZOLO COMPOUNDS AS PDE10 INHIBITORS<br/>[FR] COMPOSÉS TRIAZOLO EN TANT QU'INHIBITEURS DE PDE10
申请人:HOFFMANN LA ROCHE
公开号:WO2013178572A1
公开(公告)日:2013-12-05
The present invention provides compounds of formula (Ia) and (Ib) wherein R1, R2, R3 and R4 are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds inhibit PDE10A and can be used as medicaments.
The present invention discloses compounds of Formula I wherein the variables in Formula I are defined as described herein. Also disclosed are pharmaceutical compositions containing such compounds and methods for using the compounds of Formula I in the prevention or treatment of HCV infection.
The present invention provides compounds of formula (Ia) and (Ib)
wherein R
1
, R
2
, R
3
and R
4
are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds inhibit PDE10A and can be used as medicaments.